Winchester Office LLC announced today it has signed a lease with Artizan Biosciences at Winchester Works, a technology and life sciences building anchored by New Haven’s Science Park and located across the street from Yale’s Science Hill.
NEW HAVEN, CT – Artizan Biosciences, a biotechnology company creating gut exclusive microbial metalloprotease inhibitors (GEMMi), a new class of transformative precision therapeutics that disrupt chronic inflammatory disease triggers, will occupy 10,000 square feet of Class A lab and office space at the site. Winchester Office LLC comprises LMXD (an affiliated company of L+M Development Partners), Twining Properties, and the Goldman Sachs Urban Investment Group.
“We are incredibly excited to welcome Artizan Biosciences to our growing community,” said Jake Pine, Senior Director at LMXD. “Companies like Artizan Biosciences play a critical role in advancing life-changing research and development and Winchester Works has been specifically designed to support these needs. The Science Park campus not only offers direct access to local talent and the region’s top institutions but also provides tenants with the world-class lab and office space they need to be successful.”
“As we continue to grow our staff and expand our clinical efforts, moving to Winchester Works allows us to accelerate our research efforts. We’re excited to remain in the burgeoning life sciences community of New Haven and close to the company’s beginnings at Yale University,” said Bridget Martell, M.A., M.D., Artizan’s President and CEO.
With 93,000 square feet of space already leased at Winchester Works, the addition of Artizan Biosciences underscores how the campus’ unique ecosystem continues to attract innovative and rapidly growing life sciences tenants. Currently located at 25 Science Park, Artizan Biosciences is moving to Winchester Works to accommodate its expanding research and development efforts. This state-of-the-art lab and office space will allow Artizan Biosciences to continue advancing its lead product candidate, ARZC-001, a novel, oral, gut-restricted potent small molecule inhibitor for the treatment of inflammatory bowel disease (IBD) toward the clinic. The space also allows Artizan to leverage additional possibilities using its proprietary IgA-SEQ™ technology platform as the company expands its treatment portfolio.
Founded with preeminent immunobiology expertise from Yale University, Artizan’s novel platform disrupts intestinal triggers of the inflammation process within precise patient subsets in certain cancers and gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases. In addition to ARZC-001, Artizan is advancing additional late preclinical stage candidates for IBD and has a Parkinson’s disease therapeutic discovery and development program.
About Winchester Works
Built in 2012, the approximately 130,000-square-foot Class A office building at 115 Munson Street was the first new office building constructed in New Haven in more than 20 years. Winchester Office LLC purchased the property in late 2019 and has reimagined the building with life sciences tenants in mind, overhauling the entrance and lobby and revamping the rooftop amenity space.
Winchester Works is the first stage in the Winchester Center master plan, which could eventually include the four development sites in Science Park at Yale, all part of New Haven CT’s former Winchester Factory that once employed 25,000 people. Winchester Center could eventually include over 1,000 apartments, retail space and 500,000 square feet of office and lab space.
LMXD is the mixed-income development affiliate of L+M Development Partners Inc., one of the nation’s leading builders and developers of affordable housing. Building upon a successful 35-year track record on projects such as Essex Crossing and in New York and Banner Lane in Washington DC, LMXD’s mission is to develop transformative mixed-income, mixed-use projects with a focus on culture, community, and sustainability both within the New York region and across the country.
About Artizan Biosciences, Inc.
Artizan Biosciences is creating new classes of precision therapies targeting chronic inflammation and immune dysregulation by leveraging the human gut as a drug discovery tool. The Company’s novel platform disrupts intestinal triggers of the inflammation process, using multi-modality approaches, with a specific focus on small molecule inhibitors. In doing so, Artizan has created a new molecular class, GEMMi, which are gut exclusive microbial metalloprotease inhibitors. These compounds are designed to target the pathogenic mechanisms serving as inflammatory triggers in IBD patients, precisely. Artizan is creating multiple programs validated by strategic alliances that include Biohaven Pharmaceuticals, Brii Biosciences, and Crohn’s and Colitis Foundation. The Company’s lead program in inflammatory bowel disease will be in the clinic by 2023. The Artizan drug discovery platform was founded with IgA-SEQ™ technology and preeminent immunobiology expertise from Yale University, Artizan is based in New Haven, CT. For more information, please visit: www.artizanbiosciences.com.